Lung Diseases, Obstructive: all 2,584 studies

Page 5 of 26. Open to participants first (193), then studies with results posted, then the rest; newest registration first within each.

• Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.CompletedNCT01966107Phase 4Results posted
• Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)CompletedNCT01964352Phase 3Results posted
• Clinical Trials for Elderly Patients With Multiple DiseaseCompletedNCT01960907Not applicableResults posted
• Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01957163Phase 3Results posted
• Study Evaluating the Effect of Fluticasone Furoate/ Vilanterol (FF/VI) Inhalation Powder Compared With Vilanterol (VI) Inhalation Powder on Bone Mineral Density (BMD) in Subjects With Chronic Obstructive Pulmonary Disease (COPD).CompletedNCT01957150Phase 4Results posted
• Individualized Dosing Schedule of Inhaled Bronchodilator for Endotracheally Intubated COPD PatientsCompletedNCT01933984Not applicableResults posted
• Efficacy of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01922271Phase 4Results posted
• Study of Aclidinium Bromide/Formoterol Fumarate Compared With Salmeterol/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01908140Phase 3Results posted
• Physical Training and Heart Rate Variability in COPDCompletedNCT01889563Not applicableResults posted
• DISKUS vs. ELLIPTA Device Preference Study in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01868009Phase 3Results posted
• Tadalafil for Pulmonary Hypertension Due to Chronic Lung DiseaseCompletedNCT01862536Phase 2Results posted
• Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)CompletedNCT01857323Phase 3Results posted
• Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)CompletedNCT01854658Phase 3Results posted
• Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)CompletedNCT01854645Phase 3Results posted
• Differentiating the Effects of Substance P and Beta-endorphinCompletedNCT01854177Not applicableResults posted
• COPD Assessment and Management Bundle Versus Usual CareCompletedNCT01833026Not applicableResults posted
• Acute Effects of a Flutter Device in COPDCompletedNCT01832961Not applicableResults posted
• A 1-year Multi-center, Prospective, Cohort Study in Patients With Chronic Obstructive Pulmonary Disease Treated With Long-acting BronchodilatorCompletedNCT01794780Phase 4Results posted
• Effect of Symbicort ® on GR in Sputum in COPDCompletedNCT01787097Phase 4Results posted
• QVA vs. Salmeterol/Fluticasone, 52-week Exacerbation Study, FLAME (EFfect of Indacaterol Glycopyronium Vs Fluticasone Salmeterol on COPD Exacerbations)CompletedNCT01782326Phase 3Results posted
• Changes in Cardiac Function in COPD Patients After Administration of Budesonide/Formoterol (Symbicort®) Versus PlaceboTerminatedNCT01760304Phase 4Results posted
• Roflumilast on Markers of Bone Metabolism and Endothelial Function in COPDCompletedNCT01745848Phase 4Results posted
• Doxycycline for COPD in HIV-Infected PatientsCompletedNCT01744093Not applicableResults posted
• Early Warning SystemCompletedNCT01741480Not applicableResults posted
• A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.CompletedNCT01727141Phase 3Results posted
• Study Evaluating Preference, Satisfaction And Correct Use Of Inhalers In COPD PatientsCompletedNCT01727024Phase 4Results posted
• NVA237 BID Versus Placebo Twelve-week Efficacy StudyCompletedNCT01715298Phase 3Results posted
• Effects of Symbicort on the Ventilatory KinematicsTerminatedNCT01712854Phase 4Results posted
• A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow LimitationCompletedNCT01712516Phase 3Results posted
• A 26-week Treatment Randomized, Double-blind, Double Dummy Study to Assess the Efficacy and Safety of QVA149CompletedNCT01709903Phase 3Results posted
• NVA237 Versus Placebo 12-week Efficacy StudyCompletedNCT01709864Phase 3Results posted
• Beneficial Effects of Quercetin in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01708278Phase 1Results posted
• A Single-dose Study to Investigate the Effects of 4 Different Doses of Inhaled AZD8683 in Chronic Obstructive Pulmonary Disease (COPD) PatientsTerminatedNCT01708057Phase 2Results posted
• A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary DiseaseCompletedNCT01706536Phase 2Results posted
• A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01706328Phase 3Results posted
• 7 Days of TD-4208 in Subjects With Chronic Obstructive Pulmonary DiseaseCompletedNCT01704404Phase 2Results posted
• Long Term Safety Study of NVA237 vs QAB149 in COPD PatientsCompletedNCT01697696Phase 3Results posted
• Functional Applications of Hyperpolarized 129Xe MRITerminatedNCT01697332Phase 1/2Results posted
• A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow LimitationCompletedNCT01682863Phase 3Results posted
• Study to Compare (COPD) Assessment Test in COPD Stage III and IV in a Prophylactic TreatmentCompletedNCT01679314Not applicableResults posted
• BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With CachexiaCompletedNCT01669174Phase 2Results posted
• A Study to Evaluate Efficacy and Safety Profile of Zabofloxacin Tablet 400mg and Moxifloxacin Tablet 400mgCompletedNCT01658020Phase 3Results posted
• Efficacy and Safety of QMF149 vs. Salmeterol Xinafoate/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01636076Phase 2Results posted
• Use of FeNO to Identify Eosinophilic Inflammation in Patients Age 40 Years and Above With Chronic Obstructive Airways DiseaseCompletedNCT01634620Results posted
• Effects of ROFLUMILAST on Subclinical Atherosclerosis in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01630200Phase 4Results posted
• Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant SuitabilityCompletedNCT01615484Not applicableResults posted
• Efficacy, Safety, and Tolerability of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01613326Phase 3Results posted
• Vagus Nerve Stimulation for Management of Bronchoconstriction in Patients Hospitalized With COPD ExacerbationsTerminatedNCT01612793Results posted
• Comparison of Long-term Safety of the Combination Product QVA149A Against Placebo and Standard of Care Treatment in Chronic Obstructive Pulmonary Disease Patients With Moderate to Severe Airflow LimitationCompletedNCT01610037Phase 3Results posted
• ADOAIR250 Anti-inflammatory Effects in Japanese Subjects With Chronic Obstructive Pulmonary DiseaseCompletedNCT01607398Phase 4Results posted
• Efficacy, Safety and Tolerability of the Co-administration of NVA237 Plus Indacaterol Once Daily Versus Indacaterol Once Daily in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01604278Phase 3Results posted
• Validation of the AVAPS AE Algorithm in Chronic Obstructive Pulmonary Disease (COPD) PatientsCompletedNCT01601977Phase 2/3Results posted
• Glycopyrrolate/Formoterol Fumarate MDI Compared With Spiriva® as An Active Control in Patients With Moderate to Severe Chronic Obstructive Pulmonary DiseaseCompletedNCT01587079Phase 2Results posted
• The Role of Substance P on Perception of Breathlessness During Resistive Load BreathingCompletedNCT01580423Not applicableResults posted
• Mindfulness Mediation Intervention in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01577329Not applicableResults posted
• A Placebo-controlled Trial of Daliresp on Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01572948Not applicableResults posted
• Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01572792Phase 3Results posted
• PT001 MDI Versus Spiriva® in Patients With Moderate to Severe COPDCompletedNCT01566773Phase 2Results posted
• Efficacy, Safety and Tolerability of NVA237 in Patients With Chronic Obstructive Pulmonary DiseaseCompletedNCT01566604Phase 3Results posted
• Magnesium is Associated With QoL in COPD: A Cross-sectional StudyCompletedNCT01564953Results posted
• Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary DiseaseCompletedNCT01559116Phase 3Results posted
• Comparison of Indacaterol 150 mcg Once Daily (o.d.) With Salmeterol/Fluticasone Propionate 50 mcg/500 mcg Twice Daily (b.i.d.)CompletedNCT01555138Phase 4Results posted
• Inhaled Fluticasone Effects on Upper Airway Patency in Obstructive Lung DiseaseTerminatedNCT01554488Phase 4Results posted
• Pharmacokinetic, Safety and Tolerability Study of Aclidinium/Formoterol Fixed Dose Combination and Formoterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01551888Phase 2Results posted
• A Randomised Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01551758Phase 3Results posted
• Indacaterol 75 μg Compared to Placebo, Assessing Time to Patient's Perception of Onset of Effect in Patients With Moderate to Severe Chronic Obstructive Pulmonary DiseaseCompletedNCT01543828Phase 4Results posted
• Comparison of Safety and Efficacy of the Combination Product QVA149A Against the Concurrent Administration of the Individual Components, QAB149 and NVA237, in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01529632Phase 3Results posted
• Efficacy, Tolerability and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary DiseaseCompletedNCT01513460Phase 3Results posted
• Pharmacokinetic and Pharmacodynamic (PK and PD) Study of Fluticasone Propionate and Salmeterol Combination Product Delivered in a Capsule-based Inhaler and in a Multi-dose Dry Powder Inhaler in Moderate Asthma Patients and Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Patients.CompletedNCT01494610Phase 1/2Results posted
• The Effect of QVA149 on Patient Reported Dyspnea in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01490125Phase 3Results posted
• Tiotropium (18mcg) in Chronic Obstructive Pulmonary Disease (COPD) Patients With a Respiratory InfectionCompletedNCT01483625Phase 4Results posted
• Effect of Roflumilast at Acute Exacerbations of Chronic Obstructive Pulmonary DiseaseTerminatedNCT01473758Phase 2Results posted
• Efficacy and Safety of Aclidinium Bromide 400 µg BID (Twice a Day)Compared to Placebo in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01471171Phase 3Results posted
• Long-term Efficacy and Safety of Aclidinium Bromide/Formoterol Fumarate Fixed-Dose CombinationCompletedNCT01462942Phase 3Results posted
• Efficacy and Safety of Aclidinium Bromide 400 µg Compared to Placebo and to Tiotropium Bromide in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01462929Phase 3Results posted
• A Study to Evaluate the Efficacy of MEDI8968 in Chronic Obstructive Pulmonary DiseaseCompletedNCT01448850Phase 2Results posted
• Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS)CompletedNCT01443845Phase 4Results posted
• Effects of Ventavis in Patients With Pulmonary Hypertension (PH) Secondary to Chronic Obstructive Pulmonary Disease (COPD)TerminatedNCT01437878Phase 2Results posted
• Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary DiseaseCompletedNCT01437540Phase 3Results posted
• Efficacy, Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01437397Phase 3Results posted
• Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01431287Phase 3Results posted
• Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01431274Phase 3Results posted
• Effectiveness of Interventions to Teach Respiratory Inhaler Technique (E-TRaIN)CompletedNCT01426581Not applicableResults posted
• Study to Investigate the Dose Response, Safety and Efficacy of Nebulized EP-101(SUN101) in Patients With Chronic Obstructive Pulmonary Disease (COPD): GOLDEN-1 StudyCompletedNCT01426009Phase 2Results posted
• Single Dose Study to Assess Efficacy and Safety of 4 Doses of LAS100977 in Chronic Obstructive Pulmonary Disease (COPD) PopulationCompletedNCT01425814Phase 2Results posted
• Efficacy and Tolerability Study in Severe Chronic Obstructive Pulmonary Disease (COPD) PatientsCompletedNCT01415518Phase 4Results posted
• Nitric Oxide Bioavailability in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01398943Not applicableResults posted
• Efficacy and Tolerability of Symbicort as an add-on Treatment to Spiriva Compare With Spiriva Alone in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01397890Phase 4Results posted
• Efficacy of Inhaling Bronchodilator Medications in Chronic Obstructive Pulmonary DiseaseCompletedNCT01391559Not applicableResults posted
• Efficacy and Safety Study of Tesamorelin in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Muscle WastingTerminatedNCT01388920Phase 2Results posted
• Outcomes From Initial Maintenance Therapy With Fluticasone Propionate 250/Salmeterol 50 (FSC) or Tiotropium in Chronic Obstructive Pulmonary DiseaseCompletedNCT01387178Results posted
• Study Evaluating Preference, Satisfaction and Ease of Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD) Diagnosed PatientsCompletedNCT01385696Phase 3Results posted
• Fluticasone Propionate-salmeterol Combination Adherence in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01381471Results posted
• Impact of Initiating Tiotropium Alone Versus Initiating Tiotropium in Combination With Fluticasone Propionate/Salmeterol Xinafoate Combination (FSC) on Chronic Obstructive Pulmonary Disease-related Outcomes in Patients With Pre-existing ExacerbationsCompletedNCT01381406Results posted
• Effects of Vibration Training on Exercise Capacity in COPD-patientsCompletedNCT01380639Not applicableResults posted
• Effect of Ketoconazole on BreathlessnessCompletedNCT01378520Phase 4Results posted
• Effects of the Breathe Technologies Ventilation System in Subjects With Chronic Obstructive Pulmonary DiseaseCompletedNCT01372462Not applicableResults posted
• A Randomized, Double Blind, Placebo Controlled, Incomplete Block, Crossover, Dose Ranging Study to Evaluate the Dose Response of GSK573719 Administered Once or Twice Daily Over 7 Days in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01372410Phase 2Results posted
• Non-invasive Ventilation System in Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01355978Not applicableResults posted
• PT001 MDI Versus Atrovent Study in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01350128Phase 2Results posted

← Lung Diseases, Obstructive overview